FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Park Andrea Eun Jae 2. Date of Event Requiring Statement (MM/DD/YYYY)
5/15/2020 

 3. Issuer Name and Ticker or Trading Symbol AgeX Therapeutics, Inc. [AGE]
(Last)       (First)       (Middle)
C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVENUE, SUITE 101		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Financial Officer /
(Street)
ALAMEDA, CA 94501      
(City)             (State)             (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.0001 par value  351  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock   (1) 9/30/2029  Common Stock  20000  $1.77  D   
Option to Purchase Common Stock   (2) 5/14/2030  Common Stock  300000  $0.738  D   

Explanation of Responses:
(1)  One quarter shall vest on October 1, 2020 and the remaining shall vest monthly over 36 months, based upon continuous service.
(2)  One quarter shall vest on May 15, 2021 and the remaining shall vest monthly over 36 months, based upon continuous service.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Park Andrea Eun Jae
C/O AGEX THERAPEUTICS, INC.
965 ATLANTIC AVENUE, SUITE 101
ALAMEDA, CA 94501

Chief Financial Officer

Signatures
/s/Andrea E. Park 5/29/2020
**Signature of Reporting Person Date